Skip to main content
OpenTrials
Completed

NCT Number: NCT00504803

Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease

Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning from HLA-mismatched PBSC or cord blood: a Pilot Study

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

CHU Sart Tilman

Liège, Liege, 4000, Belgium

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

V.1. Patients

V.1.1. Diseases

Hematological malignancies confirmed histologically and not rapidly progressing:

  • AML in CR;
  • ALL in CR;
  • CML unresponsive/intolerant to Imatinib but not in blast crisis;
  • Other myeloproliferative disorders not in blast crisis and not with extensive myelofibrosis;
  • MDS with < 5% blasts;
  • Multiple myeloma;
  • CLL;
  • Non-Hodgkin's lymphoma (aggressive NHL should have chemosensitive disease);
  • Hodgkin's disease.

V.1.2. Clinical situations

  • Theoretical indication for a standard allo-transplant, but not feasible because:
  • Age > 55 yrs;
  • Unacceptable end organ performance;
  • Patient's refusal.
  • Indication for a standard auto-transplant: perform mini-allotransplantation 2-6 months after standard autotransplant.

V.1.3. Other inclusion criteria

  • Male or female; fertile female patients must use a reliable contraception method;
  • Age < 75 yrs.
  • Informed consent given by patient or his/her guardian if of minor age.

V.1.4. Exclusion criteria

  • Any condition not fulfilling inclusion criteria;
  • HIV positive;
  • Terminal organ failure, except for renal failure (dialysis acceptable);
  • Uncontrolled infection, arrhythmia or hypertension;
  • Previous radiation therapy precluding the use of 2 Gy TBI;
  • HLA-identical donor.

V.2. PBSC donors

V.2.1. Inclusion criteria

  • Related to the recipient (sibling, parent or child) or unrelated;
  • Male or female;
  • Weight > 15 Kg (because of leukapheresis);
  • Fulfills generally accepted criteria for allogeneic PBSC donation;
  • Informed consent given by donor or his/her guardian if of minor age, as per donor center standard procedures.

V.2.2. Exclusion criteria

  • Any condition not fulfilling inclusion criteria;
  • HIV positive;
  • Unable to undergo leukapheresis because of poor vein access or other reasons.

V.2.3. HLA matching

Related or unrelated donors who have 1-2 HLA mismatches, as either :

  • One antigenic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1
  • One allelic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1
  • Two allelic mismatches at HLA-A or -B or -C or -DRB1 or -DQB1
  • One antigenic mismatch + 1 allelic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1.
  • One antigenic mismatch at -DQB1 and one other antigenic mismatch at HLA-A or -B or -C or -DRB1

V.3. Cord blood unit

Banked cord blood units will be used if they fulfill the following criteria:

  • No more than 2/6 HLA mismatches (antigenic mismatch at HLA-A or HLA-B or allelic mismatch at HLA-DRB1)
  • > 2.5 x 107 TNC/kg
  • Standard validation by FACT/Netcord criteria.

Treatment and study plan

Mesenchymal stem cell infusion

Procedure

Infusion of mesenchymal stem cells on the same day as hematopoietic stem cell infusion.

Other names: Mesenchymal stem cells

Primary outcomes

  1. Day-100 incidence of non-relapse mortality

    Time frame: 100 days

Secondary outcomes

  1. 1. Hematopoietic engraftment and graft rejection. 2. Incidence of grade II-IV and III-IV acute GVHD. 3. Immunologic reconstitution

    Time frame: 365 days

Sponsors and collaborators

Lead sponsor

University of Liege

Other

Registry information

Official study title

Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning: a Pilot Study

Important dates

Study start
2006
Primary completion
2010
Study completion
2010
First posted
Jul 20, 2007
Registry last updated
Sep 2, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.